کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5724611 1411502 2017 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Original ArticleIvacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی ریوی و تنفسی
پیش نمایش صفحه اول مقاله
Original ArticleIvacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation
چکیده انگلیسی

BackgroundExtra-oesophageal reflux (EOR) may lead to microaspiration in patients with cystic fibrosis (CF), a probable cause of deteriorating lung function. Successful clinical trials of ivacaftor highlight opportunities to understand EOR in a real world study.MethodsData from 12 patients with CF and the G551D mutation prescribed ivacaftor (150 mg bd) was collected at baseline, 6, 26 and 52 weeks. The changes in symptoms of EOR were assessed by questionnaire (reflux symptom index (RSI) and Hull airway reflux questionnaire (HARQ)).ResultsSix patients presented EOR at baseline (RSI > 13; median 13; range 2-29) and 5 presented airway reflux (HARQ > 13; median 12; range 3 to 33). Treatment with ivacaftor was associated with a significant reduction of EOR symptoms (P < 0 ∙ 04 versus baseline) denoted by the reflux symptom index and Hull airway reflux questionnaire.ConclusionIvacaftor treatment was beneficial for patients with symptoms of EOR, thought to be a precursor to microaspiration.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Cystic Fibrosis - Volume 16, Issue 1, January 2017, Pages 124-131
نویسندگان
, , , , , , , , , , , , , ,